Tofacitinib in paediatric dermatoses: a narrative review

Abstract

Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses.

Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review

“…Common side effects, such as upper respiratory tract infections, headache, and gastrointestinal discomfort were reported and no new potential risks were found. 10 Based on above-mentioned case reports, we suggest oral tofacitinib 5 mg twice a day to be a promising therapy for children and adolescents with AA (aged 8-17 years). In this treatment, hair growth occurs after 3 months of continued therapy, and evident hair regrowth (> 50%) appears after 6 months of treatment.…”

“…Common side effects, such as upper respiratory tract infections, headache, and gastrointestinal discomfort were reported and no new potential risks were found. 10 …”